Adding Velcade to standard drug treatments melphalan and prednisone can extend the lives of multiple myeloma patients who are not eligible for high-dose chemotherapy, scientists at a Spanish university reported. The combination therapy also lowered the risk of disease progression by 52% and decreased the risk of death by 40%, the lead researcher said.

Full Story:

Related Summaries